MLYS Mineralys Therapeutics, Inc.

Why the latest lorundrostat data matters for Mineralys Therapeutics investors Mineralys Therapeutics (MLYS) is back on watch after the company flagged that long term efficacy and safety results from its Transform-HTN extension study of lorundrostat will feature in a late breaking session at the American Heart Association Scientific Sessions 2026. The latest lorundrostat update comes after a choppy stretch for Mineralys Therapeutics, with the share price falling 8.65% over the past week and...

Lorundrostat advances toward December FDA decision as company ramps commercial launch.

Mineralys Therapeutics Inc (MLYS) reports positive clinical results and robust funding, but faces significant Q2 net loss and competitive pressures ahead of PDUFA date.

Moby summary of Mineralys Therapeutics, Inc.'s Q2 2026 earnings call

Mineralys Therapeutics (NASDAQ:MLYS) said it is continuing commercial-launch preparations for lorundrostat ahead of its December 22 Prescription Drug User Fee Act target date, while reporting a wider second-quarter loss driven largely by a $200 million upfront payment related to its amended agreemen

Mineralys Therapeutics (MLYS) plans to report its second quarter 2026 results on August 11, 2026, accompanied by a conference call and webcast that could clarify how investors view the stock’s recent performance. See our latest analysis for Mineralys Therapeutics. Mineralys Therapeutics’ share price has pulled back recently, with a 30 day share price return of a 4.3% decline and a year to date share price return of a 25.8% decline. However, the 1 year total shareholder return sits at 97.6%...

This executive exercised 20,407 options at $1.08 and immediately sold them at $27.28 per share.

Insider divested 2% of direct holdings via pre-planned Rule 10b5-1 trading arrangement, following a 90% stock surge over the past year.